<DOC>
	<DOCNO>NCT00235300</DOCNO>
	<brief_summary>A multicenter clinical study compare event-free survival 6 month transplant Thymoglobulin-treated Simulect-treated adult kidney transplant patient . Patients receive Thymoglobulin Simulect Day 0 Day 4 . Day 0 consider day transplant procedure . Subjects meet inclusion exclusion criterion eligible participate study . The treatment assignment random choose subject physician . Subjects monitor treatment Thymoglobulin transplant hospitalization . Additional subject monitoring occur 12 month transplant . 278 study subject enrol 28 transplant center United States Europe .</brief_summary>
	<brief_title>An Open-label , Prospective , Randomized , Multi-center , Phase II Comparative Trial Thymoglobulin Versus Simulect Prevention Delayed Graft Function Acute Allograft Rejection Renal Allograft Recipients .</brief_title>
	<detailed_description />
	<mesh_term>Delayed Graft Function</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient great equal 18 year old . Patient classify `` high risk '' acute allograft rejection DGF . Must least 1 donor 1 recipient variable high risk . Patient recipient solitary cadaveric renal allograft . Women childbearing potential must negative pregnancy test ( serum urine ) . Man woman agree practice medically acceptable contraception ( i.e . barrier pharmacologic ) minimum 3 month follow study drug administration . In addition , woman recommend practice contraception 1 year follow transplantation , per local standard . Patient agree participate study sign inform consent . Patient known contraindication administration rabbit antithymocyte globulin basiliximab . Patient history hypersensitivity basiliximab . Patient dialysisdependent time immediately prior transplantation . Patient receive investigational medication within past 30 day . Patient history malignancy within 2 year , exception adequately treat localized squamous basal cell carcinoma skin without evidence recurrence . Patient currently abuse drug alcohol . Patient know suspect active infection seropositive hepatitis B surface antigen ( HBsAg ) , hepatitis C ( HCV ) , human immunodeficiency virus ( HIV ) . Patient multiple organ transplant recipient . Patient type immunosuppression ( i.e . prior transplant recipient still immunosuppression , patient receive systemic steroid medical condition ) . Patient , , opinion investigator , significant medical psychosocial problem unstable disease state would preclude enrollment . Examples significant medical problem include , limited , morbid obesity severe cardiac disease . Kidneys implant en bloc donor le 6 year old . Kidneys donor know suspect active infection seropositive HBsAg , hepatitis B core antibody ( HBcAb ) , HCV , HIV . Kidneys donor receive investigational therapy design reduce impact ischemia reperfusion , DGF , donorrelated immune event . Donor kidney preserve cold storage ( without machine preservation ) less 16 hour , exception kidney nonheartbeating donor kidneys donor great 50 year old donor SCr 2.5mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Anti-T cell antibody</keyword>
	<keyword>Cadaveric Donor Renal Transplantation</keyword>
	<keyword>Acute Renal Allograft Rejection</keyword>
	<keyword>Induction Therapy</keyword>
</DOC>